ranibizumab

Known as: V2, RhuFab, Ranibizumab [Chemical/Ingredient], RhuFab V2 
A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1983-2018
020040019832018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Data from real-world studies of ranibizumab in neovascular (wet) age-related macular degeneration suggest that outcomes in… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic macular edema (DME) patients. DESIGN Two… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular… (More)
  • table 1
  • table 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
OBJECTIVE To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean… (More)
  • table 1
  • figure 3
  • table 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE To assess the efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of… (More)
  • table 3
  • figure 1
  • table 5
  • table 7
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE To evaluate an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of… (More)
  • table 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?